File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Aptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection

TitleAptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection
Authors
KeywordsSARS-CoV-2
aptamers
neutralization therapy
viral infections
Issue Date2021
PublisherWiley-VCH Verlag GmbH & Co. KGaA. The Journal's web site is located at https://onlinelibrary.wiley.com/journal/15213773
Citation
Angewandte Chemie (International Edition), 2021, v. 60 n. 18, p. 10266-10272 How to Cite?
AbstractThe COVID-19 pandemic caused by SARS-CoV-2 is threating global health. Inhibiting interaction of the receptor-binding domain of SARS-CoV-2 S protein (SRBD) and human ACE2 receptor is a promising treatment strategy. However, SARS-CoV-2 neutralizing antibodies are compromised by their risk of antibody-dependent enhancement (ADE) and unfavorably large size for intranasal delivery. To avoid these limitations, we demonstrated an aptamer blocking strategy by engineering aptamers’ binding to the region on SRBD that directly mediates ACE2 receptor engagement, leading to block SARS-CoV-2 infection. With aptamer selection against SRBD and molecular docking, aptamer CoV2-6 was identified and applied to prevent, compete with, and substitute ACE2 from binding to SRBD. CoV2-6 was further shortened and engineered as a circular bivalent aptamer CoV2-6C3 (cb-CoV2-6C3) to improve the stability, affinity, and inhibition efficacy. cb-CoV2-6C3 is stable in serum for more than 12 h and can be stored at room temperature for more than 14 days. Furthermore, cb-CoV2-6C3 binds to SRBD with high affinity (Kd=0.13 nM) and blocks authentic SARS-CoV-2 virus with an IC50 of 0.42 nM.
DescriptionBronze open access
Persistent Identifierhttp://hdl.handle.net/10722/305859
ISSN
2023 Impact Factor: 16.1
2023 SCImago Journal Rankings: 5.300
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSun, M-
dc.contributor.authorLiu, S-
dc.contributor.authorWei, X-
dc.contributor.authorWan, S-
dc.contributor.authorHuang, M-
dc.contributor.authorSong, T-
dc.contributor.authorLu, Y-
dc.contributor.authorWeng, X-
dc.contributor.authorZhu, L-
dc.contributor.authorChen, H-
dc.contributor.authorSong, Y-
dc.contributor.authorYang, C-
dc.date.accessioned2021-10-20T10:15:21Z-
dc.date.available2021-10-20T10:15:21Z-
dc.date.issued2021-
dc.identifier.citationAngewandte Chemie (International Edition), 2021, v. 60 n. 18, p. 10266-10272-
dc.identifier.issn1433-7851-
dc.identifier.urihttp://hdl.handle.net/10722/305859-
dc.descriptionBronze open access-
dc.description.abstractThe COVID-19 pandemic caused by SARS-CoV-2 is threating global health. Inhibiting interaction of the receptor-binding domain of SARS-CoV-2 S protein (SRBD) and human ACE2 receptor is a promising treatment strategy. However, SARS-CoV-2 neutralizing antibodies are compromised by their risk of antibody-dependent enhancement (ADE) and unfavorably large size for intranasal delivery. To avoid these limitations, we demonstrated an aptamer blocking strategy by engineering aptamers’ binding to the region on SRBD that directly mediates ACE2 receptor engagement, leading to block SARS-CoV-2 infection. With aptamer selection against SRBD and molecular docking, aptamer CoV2-6 was identified and applied to prevent, compete with, and substitute ACE2 from binding to SRBD. CoV2-6 was further shortened and engineered as a circular bivalent aptamer CoV2-6C3 (cb-CoV2-6C3) to improve the stability, affinity, and inhibition efficacy. cb-CoV2-6C3 is stable in serum for more than 12 h and can be stored at room temperature for more than 14 days. Furthermore, cb-CoV2-6C3 binds to SRBD with high affinity (Kd=0.13 nM) and blocks authentic SARS-CoV-2 virus with an IC50 of 0.42 nM.-
dc.languageeng-
dc.publisherWiley-VCH Verlag GmbH & Co. KGaA. The Journal's web site is located at https://onlinelibrary.wiley.com/journal/15213773-
dc.relation.ispartofAngewandte Chemie (International Edition)-
dc.rightsSubmitted (preprint) Version This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Accepted (peer-reviewed) Version This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.subjectSARS-CoV-2-
dc.subjectaptamers-
dc.subjectneutralization therapy-
dc.subjectviral infections-
dc.titleAptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection-
dc.typeArticle-
dc.identifier.emailLiu, S: siwenliu@hku.hk-
dc.identifier.emailChen, H: hlchen@hku.hk-
dc.identifier.authorityChen, H=rp00383-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/anie.202100225-
dc.identifier.pmid33561300-
dc.identifier.pmcidPMC8014204-
dc.identifier.scopuseid_2-s2.0-85102382904-
dc.identifier.hkuros327457-
dc.identifier.volume60-
dc.identifier.issue18-
dc.identifier.spage10266-
dc.identifier.epage10272-
dc.identifier.isiWOS:000627043700001-
dc.publisher.placeGermany-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats